What are the available dosages and capsule strengths of nabilone?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Nabilone Dosing and Available Strengths

Nabilone is available as 1 mg oral capsules, with dosing initiated at 1 mg twice daily and titrated up to a maximum of 2 mg four times daily (8 mg/day total). 1, 2

Available Formulations

  • Capsule strength: 1 mg only 2
  • Route: Oral administration 2

Dosing Regimens

For Chemotherapy-Induced Nausea and Vomiting (CINV)

Starting dose: 1 mg twice daily
Titration: Up-titrate as needed
Maximum dose: 2 mg four times daily (8 mg/day total) 1

The ASCO guideline specifically recommends this dosing for refractory CINV due to moderate to highly emetogenic chemotherapy, using nabilone as a salvage antiemetic when standard therapies fail.

Dosing Approach: "Start Low, Go Slow"

  • Begin at the lower end of the dosing range (1 mg twice daily)
  • Titrate gradually based on therapeutic response and tolerability 1
  • Peak plasma concentrations occur within 2 hours of oral administration 2
  • The plasma half-life of nabilone itself is approximately 2 hours, though metabolites have a longer half-life of about 35 hours 2

Important Dosing Considerations

No dose adjustments required for:

  • Renal impairment 1
  • Hepatic impairment 1

Key clinical caveat: While no formal dose adjustments are required, adverse effects and drug interactions can be significant dose-limiting barriers, particularly in older adults with cancer who often experience polypharmacy 1. The most common dose-related adverse effects include drowsiness, dizziness, vertigo, euphoria, and dry mouth 1, 2.

Pharmacokinetic Profile

  • Bioavailability: Complete absorption from GI tract 2
  • Food effect: Food does not significantly affect rate or extent of absorption 2
  • Volume of distribution: Approximately 12.5 L/kg 2
  • Dose linearity: Exhibits linear pharmacokinetics within therapeutic range 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.